Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
HPLC analysis and purification of peptides
The Drug Boom That Needs a Fridge Most injectable GLP-1 drugs, such as Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound, require cold-chain conditions during transport
The FDA seeks to bar bulk compounding of semaglutide, tirzepatide, and liraglutide, spotlighting risks in online glucagon-like peptide-1 copies
Its also important to understand how these changes affect which medications patients receive at the pharmacy, and weve released a companion report that uses dispense data to examine switching patterns
Clinical Trial Results STEP Trials (Semaglutide) The STEP program studied semaglutide 2.4 mg weekly in overweight/obese adults: STEP 1 : 16.9% average weight loss over 68 weeks vs 2.4% placebo STEP 2 (T2D patients): 9.6% weight loss STEP 3 (with behavioral therapy): 16.0% weight loss STEP 5 (2-year data): 15.2% sustained weight loss SURMOUNT Trials (Tirzepatide) The SURMOUNT program studied tirzepatide at 5mg, 10mg, and 15mg weekly: SURMOUNT-1 : 20.9% average weight loss at 15mg over 72 weeks vs 3.1% placebo SURMOUNT-2 (T2D patients): 14.7% at 15mg SURMOUNT-3 (with lifestyle intervention): 26.6% at highest dose SURMOUNT-4 (maintenance): continued weight loss vs weight regain on placebo Head-to-Head No large head-to-head trial has directly compared them at optimal doses for weight loss
US$ 22.68
US$ 23.57
US$ 23.44
US$ 22.22
US$ 25.59
US$ 28.62
US$ 29.72
US$ 28.41
US$ 24.23
US$ 21.90
US$ 20.27
